caus
agent
sever
acut
respiratori
syndrom
sar
identifi
coronaviru
cov
follow
outbreak
current
licens
vaccin
treatment
sarscov
infect
potenti
prevent
control
strategi
show
promis
vitro
must
evalu
anim
model
age
balbc
mous
model
sar
support
high
level
viral
replic
associ
clinic
ill
diseas
mimic
sar
elderli
test
two
prevent
strategi
vaccin
passiv
transfer
serum
antibodi
determin
extent
protect
achiev
sarscov
challeng
model
approach
abl
achiev
induc
antibodi
titer
suffici
reduc
viral
load
protect
weight
loss
reduc
elimin
histopatholog
chang
lung
age
mice
studi
valid
util
age
balbc
mous
model
evalu
efficaci
vaccin
immunoprophylaxi
publish
elsevi
ltd
agent
caus
sever
acut
respiratori
syndrom
sar
outbreak
identifi
sequenc
analysi
immunofluoresc
coronaviru
viru
sarscov
sarscov
zoonosi
although
close
relat
virus
identifi
civet
cat
chines
horsesho
bat
anim
reservoir
viru
introduc
human
popul
yet
definit
identifi
sinc
juli
sar
outbreak
end
case
communityacquir
laboratoryacquir
infect
occur
presenc
anim
reservoir
natur
suggest
risk
reintroduct
sarslik
cov
human
remain
effort
develop
prevent
strategi
continu
anim
model
need
effect
test
prevent
strategi
sever
anim
speci
includ
inbr
strain
mice
found
support
viral
replic
absenc
clinic
ill
howev
anim
model
mimic
natur
cours
diseas
afford
stringent
test
potenti
intervent
sever
case
seri
sar
patient
advanc
age
risk
factor
sever
diseas
requir
intens
care
ventilatori
support
well
increas
mortal
found
old
balbc
mice
support
high
prolong
level
viral
replic
lung
sign
clinic
ill
histopatholog
chang
lung
includ
sign
acut
organ
diffus
alveolar
damag
dad
thu
model
reflect
find
elderli
patient
sar
activ
passiv
immun
two
standard
approach
prevent
viral
infect
consid
sar
evalu
young
old
balbc
mice
passiv
transfer
postinfect
hyperimmun
antiserum
deriv
sarscov
infect
mice
shown
effect
protect
immunolog
young
mice
subsequ
challeng
intranas
administ
sarscov
attenu
recombin
vesicular
stomat
viru
rvsv
known
good
vector
express
foreign
protein
induc
humor
antibodi
cell
mediat
immun
express
protein
rvsv
vaccin
express
hiv
gag
env
protein
induc
strong
longlast
antibodi
recal
attenu
rvsv
viru
express
sarscov
spike
protein
effici
express
sarscov
protein
confer
longlast
protect
viral
challeng
young
mice
select
two
prevent
strategi
effect
young
mice
evalu
old
mice
determin
immunoprophylact
measur
effect
young
mous
also
effect
suscept
age
mous
test
efficaci
passiv
transfer
postinfect
murin
sar
antiserum
activ
immun
rvsv
vaccin
encod
sar
protein
rvsv
protect
challeng
intranas
administ
sarscov
model
postinfect
hyperimmun
sar
antiserum
gener
balbc
mice
follow
intranas
intraperiton
ip
inject
sarscov
urbani
efficaci
passiv
transfer
test
mice
group
receiv
antiserum
ip
inject
neg
control
group
receiv
normal
nonimmun
balbc
mous
sera
harlan
indianapoli
ia
experiment
group
receiv
either
undilut
postinfect
hyperimmun
sar
antiserum
dilut
pb
antiserum
sera
recipi
mice
collect
h
ip
inject
determin
neutral
antibodi
level
achiev
neutral
antibodi
titer
determin
microneutr
assay
vero
cell
monolay
mice
challeng
tcid
sarscov
urbani
day
postinfect
pi
viru
titer
lung
expect
peak
four
mice
per
group
sacrif
lung
harvest
determin
level
viru
present
briefli
lung
homogen
wv
suspens
clarifi
low
speed
centrifug
titer
vero
monolay
plate
infecti
viru
neutral
ex
vivo
lung
homogen
affect
viru
titer
confirm
presenc
viru
lung
homogen
quantit
pcr
total
rna
isol
purifi
wv
lung
homogen
use
rneasi
mini
kit
qiagen
valencia
ca
oncolumn
dnase
digest
per
manufactur
protocol
rna
concentr
determin
g
revers
transcrib
use
random
primer
includ
stratascript
firststrand
synthesi
system
stratagen
la
jolla
ca
pcr
reaction
perform
c
total
cycl
use
brilliant
sybr
green
qpcr
master
mix
stratagen
multiplex
quantit
pcr
system
stratagen
sar
genom
rna
amplifi
use
forward
primer
ggtgacggcaaaatgaaagagc
revers
primer
ggagaatttcccctactg
rrna
amplifi
sampl
intern
control
use
ggtacagtgaaactgcgaat
cagttatccaagtaggagag
c
cycl
number
doubl
strand
dna
detect
background
level
four
mice
per
group
sacrif
day
pi
evalu
histopatholog
chang
time
point
select
day
pi
viral
antigen
focal
interstiti
inflamm
present
clearanc
antigen
accompani
histopatholog
chang
indic
lung
repair
visibl
day
pi
lung
inflat
formalin
process
histopatholog
examin
pulmonari
histopatholog
evalu
distribut
sarscov
antigen
determin
immunohistochem
ihc
stain
vaccin
studi
mice
receiv
one
three
follow
intervent
inocul
pfu
rvsv
vaccin
pfu
rvsv
vector
without
foreign
gene
neg
control
tcid
sarscov
urbani
posit
control
protect
subsequ
challeng
sera
collect
day
postvaccin
postinfect
determin
neutral
antibodi
titer
achiev
mice
challeng
day
later
tcid
sarscov
urbani
determin
efficaci
vaccin
four
mice
per
vaccin
group
weigh
daili
week
day
postchalleng
four
mice
per
group
sacrif
lung
harvest
determin
titer
infecti
viru
passiv
transfer
undilut
dilut
postinfect
sarscov
hyperimmun
murin
antisera
achiev
signific
neutral
antibodi
titer
recipi
mice
fig
mice
receiv
undilut
hyperimmun
sera
mean
neutral
antibodi
titer
mice
receiv
dilut
sar
hyperimmun
antisera
lefthand
yaxi
mean
viral
titer
lung
express
log
tcid
g
tissu
lower
limit
detect
log
tcid
g
error
bar
repres
se
p
pairwis
comparison
test
group
control
group
receiv
nonimmun
mous
serum
righthand
yaxi
reciproc
mean
antibodi
titer
express
log
dilut
serum
antibodi
neutral
tcid
sarscov
lower
limit
detect
error
bar
repres
se
p
pairwis
comparison
test
group
control
group
receiv
nonimmun
mous
serum
mean
neutral
titer
contrast
mice
receiv
normal
nonimmun
mous
serum
detect
neutral
antibodi
titer
limit
detect
differ
statist
signific
p
mannwhitney
u
test
mice
receiv
sar
hyperimmun
murin
antisera
protect
pulmonari
viru
replic
challeng
sarscov
viru
detect
lung
mice
receiv
undilut
sar
hyperimmun
antiserum
mice
receiv
dilut
sar
hyperimmun
antiserum
reduct
viral
titer
compar
mice
receiv
nonimmun
mous
serum
tcid
g
respect
p
mannwhitney
u
test
reduct
titer
infecti
viru
confirm
use
realtim
pcr
data
present
mean
cycl
number
c
rrna
ngene
sarscovspecif
rna
respect
amplifi
background
c
valu
mice
receiv
hyperimmun
antisera
mice
receiv
dilut
hyperimmun
antisera
mice
receiv
nonimmun
sera
signific
differ
c
valu
amplif
rrna
three
group
kruskalw
p
signific
differ
among
three
group
amplif
sarscov
rna
kruskalw
p
sarscov
rna
amplifi
lung
mice
receiv
undilut
hyperimmun
serum
reduct
viral
load
lung
mice
receiv
dilut
hyperimmun
serum
compar
mice
receiv
nonimmun
serum
histopatholog
examin
lung
mice
receiv
nonimmun
mous
sera
multipl
perivascular
foci
mononuclear
inflammatori
infiltr
day
day
postvaccin
three
four
mice
receiv
rvsv
vaccin
achiev
detect
neutral
antibodi
titer
lower
limit
detect
fourth
mous
detect
neutral
antibodi
respons
tabl
mice
receiv
vector
alon
rvsv
detect
neutral
antibodi
respons
control
group
mice
infect
sarscov
achiev
signific
mean
neutral
antibodi
titer
day
postinfect
although
mice
vaccin
rvsv
low
neutral
titer
day
postvaccin
partial
protect
weight
loss
well
pulmonari
viru
replic
upon
sarscov
challeng
day
postchalleng
mice
immun
rvsv
lost
prechalleng
weight
rvsv
vaccin
mice
lost
less
prechalleng
bodi
weight
maximum
mean
chang
weight
day
challeng
occur
day
postchalleng
rvsv
vaccin
mice
lost
pre
challeng
weight
day
postchalleng
sarscov
rvsv
treat
group
began
regain
weight
respect
tabl
rvsv
vaccin
mice
mean
pulmonari
viral
titer
day
postchalleng
tcid
g
one
mous
group
complet
protect
remain
three
mice
viral
replic
reduc
compar
mice
receiv
vector
alon
mice
previous
infect
sarscov
subsequ
challeng
day
complet
protect
pulmonari
viral
replic
group
statist
signific
reduct
mean
pulmonari
viral
titer
compar
rvsv
control
group
tcid
g
p
tabl
sever
acut
respiratori
syndrom
caus
novel
coronaviru
sarscov
spread
human
popul
countri
matter
month
control
outbreak
achiev
use
stringent
public
health
measur
although
diseas
reappear
epidem
form
sinc
relat
virus
identifi
anim
may
reintroduc
human
event
viru
reemerg
human
popul
specif
prevent
strategi
avail
implement
along
public
health
measur
number
anim
model
evalu
studi
sarscov
prevent
control
golden
syrian
hamster
model
use
studi
control
infect
monoclon
antibodi
mab
administ
prophylaxi
treatment
use
postexposur
mab
abl
alter
cours
sever
sarscov
infect
hamster
hamster
model
like
age
mous
model
support
replic
viru
presenc
signific
patholog
chang
lung
studi
demonstr
util
age
balbc
mous
model
evalu
vaccin
immunoprophylaxi
age
mous
model
differ
young
mous
model
measur
efficaci
quantit
virolog
viral
replic
lung
young
mice
occur
absenc
clinic
ill
extrapulmonari
spread
elev
proinflammatori
cytokin
peak
pulmonari
viral
titer
around
tcid
g
seen
day
postinfect
clearanc
day
histopatholog
exam
two
day
postinfect
reveal
mild
focal
peribronchiolar
mononuclear
inflammatori
infiltr
clearanc
viral
antigen
day
age
mice
allow
analysi
four
outcom
measur
quantit
virolog
clinic
symptom
histopatholog
chang
immunohistochemistri
lung
high
titer
viral
replic
accompani
signific
weight
loss
day
postinfect
nadir
day
postinfect
extrapulmonari
spread
liver
day
peak
pulmonari
viral
titer
tcid
g
seen
day
postinfect
evid
viral
replic
high
titer
day
multifoc
interstiti
lymphocyt
infiltr
seen
histopatholog
day
gradual
resolut
repair
day
postinfect
complet
protect
sarscov
infect
age
mice
demonstr
anim
achiev
high
level
neutral
antibodi
seen
age
mice
passiv
immun
use
murin
sar
hyperimmun
antisera
even
low
level
sarscovspecif
neutral
antibodi
passiv
immun
mice
partial
protect
viral
infect
greater
reduct
viral
titer
observ
mice
receiv
dilut
hyperimmun
antisera
compar
mice
receiv
nonimmun
mous
serum
prior
challeng
reduct
extent
durat
lung
inflamm
seen
viral
load
reduc
level
signific
inflamm
found
mice
achiev
steril
immun
thu
prior
administr
sar
hyperimmun
anitsera
prevent
viral
replic
associ
diseas
age
balbc
mice
although
rvsv
vaccin
induc
high
prolong
antibodi
respons
young
mice
see
similar
robust
level
antibodi
respons
old
mice
two
possibl
explan
poor
antibodi
respons
sarscov
follow
immun
age
mice
rvsv
either
rvsv
replic
effici
respons
old
mice
sarscov
spike
protein
poor
antibodi
titer
vsv
mice
robust
data
shown
suggest
latter
explan
like
reduct
viral
load
protect
weight
loss
histopatholog
chang
seen
mice
immun
rvsv
vaccin
compar
mice
receiv
rvsv
surpris
find
protect
occur
absenc
high
neutral
antibodi
level
protect
rvsv
vector
vaccin
mediat
strong
humor
cytotox
lymphocyt
ctl
respons
ctl
respons
part
respons
rapid
control
clearanc
mani
viral
infect
although
antibodi
may
contribut
protect
specul
efficaci
rvsv
old
mice
result
strong
ctl
respons
specul
support
observ
although
neutral
antibodi
titer
lower
reduct
pulmonari
viru
replic
greater
mice
immun
rvsv
mice
passiv
immun
dilut
hyperimmun
sar
antiserum
age
mous
model
mimic
find
elderli
sar
patient
proven
use
tool
evalu
strategi
prevent
sarscov
infect
studi
passiv
antibodi
transfer
vaccin
live
viru
vaccin
effect
strategi
control
viral
replic
associ
diseas
